% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jiang:255501,
      author       = {Jiang, Nan and Leithold, Leonie H. E. and Post, Julia and
                      Ziehm, Tamar and Mauler, Jörg and Gremer, Lothar and
                      Cremer, Markus and Schartmann, Elena and Shah, N. J. and
                      Kutzsche, Janine and Langen, Karl-Josef and Breitkreutz,
                      Jörg and Willbold, Dieter and Willuweit, Antje},
      title        = {{P}reclinical {P}harmacokinetic {S}tudies of the {T}ritium
                      {L}abelled {D}-{E}nantiomeric {P}eptide {D}3 {D}eveloped for
                      the {T}reatment of {A}lzheimer´s {D}isease},
      journal      = {PLoS one},
      volume       = {10},
      number       = {6},
      issn         = {1932-6203},
      address      = {Lawrence, Kan.},
      publisher    = {PLoS},
      reportid     = {FZJ-2015-05663},
      pages        = {e0128553 -},
      year         = {2015},
      abstract     = {Targeting toxic amyloid beta (Aβ) oligomers is currently a
                      very attractive drug development strategy for treatment of
                      Alzheimer´s disease. Using mirror-image phage display
                      against Aβ1-42, we have previously identified the fully
                      D-enantiomeric peptide D3, which is able to eliminate Aβ
                      oligomers and has proven therapeutic potential in transgenic
                      Alzheimer´s disease animal models. However, there is little
                      information on the pharmacokinetic behaviour of
                      D-enantiomeric peptides in general. Therefore, we conducted
                      experiments with the tritium labelled D-peptide D3 (3H-D3)
                      in mice with different administration routes to study its
                      distribution in liver, kidney, brain, plasma and
                      gastrointestinal tract, as well as its bioavailability by
                      i.p. and p.o. administration. In addition, we investigated
                      the metabolic stability in liver microsomes, mouse plasma,
                      brain, liver and kidney homogenates, and estimated the
                      plasma protein binding. Based on its high stability and long
                      biological half-life, our pharmacokinetic results support
                      the therapeutic potential of D-peptides in general, with D3
                      being a new promising drug candidate for Alzheimer´s
                      disease treatment.},
      cin          = {INM-1 / INM-4 / ICS-6},
      ddc          = {500},
      cid          = {I:(DE-Juel1)INM-1-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      I:(DE-Juel1)ICS-6-20110106},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000355652200078},
      pubmed       = {pmid:26046986},
      doi          = {10.1371/journal.pone.0128553},
      url          = {https://juser.fz-juelich.de/record/255501},
}